REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

Robert K. Stuart, Larry Cripe, Michael B. Maris, Maureen A. Cooper, Richard M. Stone, Shaker R. Dakhil, Francesco Turturro, Wendy Stock, James Mason, Paul J. Shami, Stephen A. Strickland, Luciano J. Costa, Gautam Borthakur, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Farhad Ravandi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m2 d 1, 8, 15; B: 72 mg/m2 d 1, 8; C: 72 mg/m2 or 90 mg/m2 d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Common (>20%) grade ≥3 adverse events were thrombocytopenia, febrile neutropenia, anaemia, neutropenia, sepsis, pneumonia, stomatitis and hypokalaemia. Overall CR and CR/CRp rates were 29% and 32%; median overall survival (OS) was 7·0 months; 1-year OS was 34%. Schedule C (72 mg/m2) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24%) and 30-d (7%) and 60-d (17%) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31% and 35%, median OS was 7·7 months and 1-year OS was 38%. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m2 d 1, 4 is recommended for further study in this population. Registered at www.clinicaltrials.gov: #NCT00607997.

Original languageEnglish (US)
Pages (from-to)796-805
Number of pages10
JournalBritish Journal of Haematology
Volume168
Issue number6
DOIs
StatePublished - Mar 1 2015

Fingerprint

Acute Myeloid Leukemia
Survival
Sepsis
Appointments and Schedules
Febrile Neutropenia
Stomatitis
Hypokalemia
Mortality
Quinolones
Neutropenia
Thrombocytopenia
Anemia
Pneumonia
Blood Platelets
Safety
vosaroxin
Incidence
Population
Ts-72

Keywords

  • Acute myeloid leukaemia
  • Elderly
  • Newly diagnosed
  • Topoisomerase-II inhibitor
  • Vosaroxin

ASJC Scopus subject areas

  • Hematology

Cite this

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. / Stuart, Robert K.; Cripe, Larry; Maris, Michael B.; Cooper, Maureen A.; Stone, Richard M.; Dakhil, Shaker R.; Turturro, Francesco; Stock, Wendy; Mason, James; Shami, Paul J.; Strickland, Stephen A.; Costa, Luciano J.; Borthakur, Gautam; Michelson, Glenn C.; Fox, Judith A.; Leavitt, Richard D.; Ravandi, Farhad.

In: British Journal of Haematology, Vol. 168, No. 6, 01.03.2015, p. 796-805.

Research output: Contribution to journalArticle

Stuart, RK, Cripe, L, Maris, MB, Cooper, MA, Stone, RM, Dakhil, SR, Turturro, F, Stock, W, Mason, J, Shami, PJ, Strickland, SA, Costa, LJ, Borthakur, G, Michelson, GC, Fox, JA, Leavitt, RD & Ravandi, F 2015, 'REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia', British Journal of Haematology, vol. 168, no. 6, pp. 796-805. https://doi.org/10.1111/bjh.13214
Stuart, Robert K. ; Cripe, Larry ; Maris, Michael B. ; Cooper, Maureen A. ; Stone, Richard M. ; Dakhil, Shaker R. ; Turturro, Francesco ; Stock, Wendy ; Mason, James ; Shami, Paul J. ; Strickland, Stephen A. ; Costa, Luciano J. ; Borthakur, Gautam ; Michelson, Glenn C. ; Fox, Judith A. ; Leavitt, Richard D. ; Ravandi, Farhad. / REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. In: British Journal of Haematology. 2015 ; Vol. 168, No. 6. pp. 796-805.
@article{5588cd3e541448458e0ec0d1f421867e,
title = "REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia",
abstract = "This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m2 d 1, 8, 15; B: 72 mg/m2 d 1, 8; C: 72 mg/m2 or 90 mg/m2 d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Common (>20{\%}) grade ≥3 adverse events were thrombocytopenia, febrile neutropenia, anaemia, neutropenia, sepsis, pneumonia, stomatitis and hypokalaemia. Overall CR and CR/CRp rates were 29{\%} and 32{\%}; median overall survival (OS) was 7·0 months; 1-year OS was 34{\%}. Schedule C (72 mg/m2) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24{\%}) and 30-d (7{\%}) and 60-d (17{\%}) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31{\%} and 35{\%}, median OS was 7·7 months and 1-year OS was 38{\%}. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m2 d 1, 4 is recommended for further study in this population. Registered at www.clinicaltrials.gov: #NCT00607997.",
keywords = "Acute myeloid leukaemia, Elderly, Newly diagnosed, Topoisomerase-II inhibitor, Vosaroxin",
author = "Stuart, {Robert K.} and Larry Cripe and Maris, {Michael B.} and Cooper, {Maureen A.} and Stone, {Richard M.} and Dakhil, {Shaker R.} and Francesco Turturro and Wendy Stock and James Mason and Shami, {Paul J.} and Strickland, {Stephen A.} and Costa, {Luciano J.} and Gautam Borthakur and Michelson, {Glenn C.} and Fox, {Judith A.} and Leavitt, {Richard D.} and Farhad Ravandi",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/bjh.13214",
language = "English (US)",
volume = "168",
pages = "796--805",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

AU - Stuart, Robert K.

AU - Cripe, Larry

AU - Maris, Michael B.

AU - Cooper, Maureen A.

AU - Stone, Richard M.

AU - Dakhil, Shaker R.

AU - Turturro, Francesco

AU - Stock, Wendy

AU - Mason, James

AU - Shami, Paul J.

AU - Strickland, Stephen A.

AU - Costa, Luciano J.

AU - Borthakur, Gautam

AU - Michelson, Glenn C.

AU - Fox, Judith A.

AU - Leavitt, Richard D.

AU - Ravandi, Farhad

PY - 2015/3/1

Y1 - 2015/3/1

N2 - This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m2 d 1, 8, 15; B: 72 mg/m2 d 1, 8; C: 72 mg/m2 or 90 mg/m2 d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Common (>20%) grade ≥3 adverse events were thrombocytopenia, febrile neutropenia, anaemia, neutropenia, sepsis, pneumonia, stomatitis and hypokalaemia. Overall CR and CR/CRp rates were 29% and 32%; median overall survival (OS) was 7·0 months; 1-year OS was 34%. Schedule C (72 mg/m2) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24%) and 30-d (7%) and 60-d (17%) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31% and 35%, median OS was 7·7 months and 1-year OS was 38%. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m2 d 1, 4 is recommended for further study in this population. Registered at www.clinicaltrials.gov: #NCT00607997.

AB - This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m2 d 1, 8, 15; B: 72 mg/m2 d 1, 8; C: 72 mg/m2 or 90 mg/m2 d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Common (>20%) grade ≥3 adverse events were thrombocytopenia, febrile neutropenia, anaemia, neutropenia, sepsis, pneumonia, stomatitis and hypokalaemia. Overall CR and CR/CRp rates were 29% and 32%; median overall survival (OS) was 7·0 months; 1-year OS was 34%. Schedule C (72 mg/m2) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24%) and 30-d (7%) and 60-d (17%) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31% and 35%, median OS was 7·7 months and 1-year OS was 38%. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m2 d 1, 4 is recommended for further study in this population. Registered at www.clinicaltrials.gov: #NCT00607997.

KW - Acute myeloid leukaemia

KW - Elderly

KW - Newly diagnosed

KW - Topoisomerase-II inhibitor

KW - Vosaroxin

UR - http://www.scopus.com/inward/record.url?scp=84924020604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924020604&partnerID=8YFLogxK

U2 - 10.1111/bjh.13214

DO - 10.1111/bjh.13214

M3 - Article

C2 - 25403830

AN - SCOPUS:84924020604

VL - 168

SP - 796

EP - 805

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -